alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
March 11, 1971

Honorable ThomasBartlett, Jr, County Attorney Falls Oounty Courthouse Marlin, Texas 76661

Dear‘Mr. Bartlett : OpiniOn No. M-807 Re: Authority of County Commlsaionera 1Court to sell unmatured U. S. Government bonds beTonglng to the Permanent School Fund of the County Por the prebent market valtie of such bonds, aaaumlng such market value to
-’ be leaa than their par value but In exceaa of their coat.prIce. In-your recent letter you’request thIa office to render an opinion on the following question:

_

“Does the CommIaalonera~ Co&t have authority to sell unmatured United States Qovernment bonds belonging to the Permanent School Fur&of the County for the present market value of’such bonda, If the market value la nowIn exceaa of the price for aUChbonds, yet less than their par value?” paid
The ~eaponaIblllty for administering the permanent school *d of a County Is vested In.the CommIaaIonera ’Court of’the
=‘untg. 17.81 andTex. Con&.

Sec. 17.82. Art.. VII, Seo. 6and Tex. Ed. Code, Sec.

These constitutional and statutory, pmvIalOna preacrlbe the type of investments the COmmiaaIOnerS’ tit can makeand provide that auah Investments “shall be held bythe county In trust for ‘the benefit of Ita publfc free schools ,I’ It has been held by this offloe that SeatIon 6OrArticle vrI of the ConatItutIon op Texas prohibited the selling of
‘a S. Government bonda belonging to the permanent ach6ol.fund Orthe county at a dieaount when such prooedure would result In dIml.hIeung the permanent school fund of the oounty, Attorney Generalfa Opinion NO’

.v-1089. However, whenbonda

-3920-Honorable Thomas Bartlett, Jr., page 2, (M-807)

are sold for a price greater than the amount of money df the permanent school find lnveated In them there would be no dlnilniahlng of the permanent eohool Lund noviolatic of Sedt1o.n 6 or Artlole VII of the Texas Constitution and .4:4;;qey Ceneral’a Opinion No, V-1089 would not be appll-

. Finding no other authority which might be construed to prohlblt the CommlaaIonerel Court from aelllng bonds belonging to.the permanent school fund at lesa than par value, it la the opinion of thla Offloe that the Commission Court doea have authority to eel1 unmatured United States, Qovernment bonds belonging to the permanent aohool fund of the oounty at a.dlacount provided the dlaoount price of the bond3 la not leas than the amount of permanent school funds inveated In aald bonda. SUMMARY

The CommIssIonera Court does have authority to sell unmatured United Statea Government bonds belonging to the permanent echo01 fund of .the county for the present market value of such bonda, If the market value la nowIn exceaa of the prloe paid for auoh bonda,*,yet leaa than their par value. Very truly youra, CRAWFORD

C. MARTIN’ Attorney General of Texas 

# ,dZ&&ti

Firs+ Ass&ant Prepared byEdEaqulvel Aaalatant Attorney ffeneral

\ APPROVED

: OPINION,COMMITTEE Kerns Taylor, Chairman W.B. Allen, Co-Chairman Pat Bailey Houghton Brownlee -3921-. .

Honorable Thomas Bartlett, Jr., page 3, (M-807)

Jack Goodman John Reeves KECADEF.MUFFIN Staff Legal Assistant ALFREDWALKER Executive Assistant

-3922-
# C_2014175EN.01002701.xml

| 10.6.2014 | EN | Official Journal of the European Union | C 175/27 |
| --- | --- | --- | --- |

10.6.2014

EN

Official Journal of the European Union

C 175/27

---

Action brought on 21 March 2014 — European Parliament v Council of the European Union

(Case C-136/14)

2014/C 175/34

Language of the case: French

Parties

Parties

Applicant: European Parliament (represented by: J. Rodrigues and L. Visaggio, acting as Agents)

Applicant:

Defendant: Council of the European Union

Defendant:

Form of order sought

Form of order sought

| — | annul Council Directive 2013/64/EU of 17 December 2013 amending Council Directives 91/271/EEC and 1999/74/EC, and Directives 2000/60/EC, 2006/7/EC, 2006/25/EC and 2011/24/EU of the European Parliament and of the Council, following the amendment of the status of Mayotte with regard to the European Union. (1) |
| --- | --- |

—

annul Council Directive 2013/64/EU of 17 December 2013 amending Council Directives 91/271/EEC and 1999/74/EC, and Directives 2000/60/EC, 2006/7/EC, 2006/25/EC and 2011/24/EU of the European Parliament and of the Council, following the amendment of the status of Mayotte with regard to the European Union. (1)

1

| — | order the Council of the European Union to pay the costs. |
| --- | --- |

—

order the Council of the European Union to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

The European Parliament seeks annulment of Directive 2013/64/EU which the Council adopted on the legal basis of Article 349 TFEU.

According to the Parliament, the legal basis chosen by the Council is incorrect, on the ground that the measures provided for in the contested directive come under the responsibilities of the European Union pursuant to various common policies. Those measures should therefore have been adopted under sector-specific legal bases concerning the areas of environment, agriculture, social policy and public health, namely Articles 43(2), 114, 153(2), 168 and 192(1) TFEU and not on the basis of Article 349 TFEU.

For the Parliament, measures which are not designed to deal with the economic or social constraints which an outermost region is facing by means of derogation from the full application of EU law in the region concerned cannot legitimately be based on the legal basis of Article 349 TFEU. Accordingly, measures which merely seek to postpone the application of certain provisions of EU law to an outermost region do not fall within the scope of that Article.

---

(1)  OJ 2013 L 353, p. 8.

1

---
§ 522.2150 Stanozolol. ( a ) *Specifications.* Each milliliter of suspension contains 50 milligrams (mg) of stanozolol.
( b ) *Sponsor.* No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount* — ( i ) *Dogs and cats.* For cats and small breeds of dogs: 25 mg. For larger dogs: 50 mg. Administer by deep intramuscular injection in the thigh at weekly intervals, for several weeks.
( ii ) *Horses.* Administer 25 mg per 100 pounds of body weight by deep intramuscular injection in the gluteal region at weekly intervals, for not more than 4 weeks.
( 2 ) *Indications for use.* For use as an anabolic steroid treatment.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16195, Mar. 25, 2014]
IN THE SUPREME COURT OF PENNSYLVANIA 

WESTERN DISTRICT 

COMMONWEALTH OF PENNSYLVANIA, 

 Respondent 

 v. 

SEAN DONTAE MCKINLEY, 

 Petitioner 

:

:

:

:

:

:

:

:

:

:

:

No. 386 WAL 2015 

Petition for Allowance of Appeal from 

the Order of the Superior Court 

ORDER 

PER CURIAM 

AND NOW, this 1st day of December, 2015, the Petition for Allowance of Appeal 

is DENIED.
IN THE SUPREME COURT OF PENNSYLVANIA

WESTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

CHARMAINE PFENDER,

Petitioner :

:

:

:

:

:

:

:

:

:

: No. 218 WAL 2017

Petition for Allowance of Appeal from

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW , this 24th day of October, 2017

, the Petition for Allowance of Appeal

is DENIED

.
**Exhibit 32.1**

 

 

CERTIFICATIONS

 

Pursuant to 18 U.S.C. § 1350, each of the undersigned officers of Windtree Therapeutics, Inc. (the “Company”) hereby certifies that our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (“Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: April 16, 2019

 

/s/ Craig Fraser                         

Craig Fraser

President and Chief Executive Officer

 

/s/ John Tattory                         

John Tattory

Senior Vice President and Chief Financial Officer

 

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.

 

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Small Business Administration

Pursuant to the authority granted to the United States Small Business Administration under the Small Business Investment Act of 1958, under Section 309 of the Act and Section 107.1900 of the Small Business Administration Rules and Regulations (13 CFR 107.1900) to function as a small business investment company under the Small business Investment Company License No. 09/79-0412 issued to Telesoft Partners, L.P., and said license is hereby declared null and void.

United States Small Business Administration.

Dated: January 5, 2010.

Sean J. Green,

AA/Investment.

[FR Doc. 2010-4292 Filed 3-2-10; 8:45 am]

BILLING CODE M
Exhibit 23.2

INDEPENDENT AUDITORS' CONSENT

We consent to the use in this  Amendment  No. 1 to  Registration  Statement  No.
333-69228  of PSEG Power LLC on Form S-4 of our  report  dated  March 21,  2001,
appearing in the Prospectus, which is a part of this Registration Statement, and
to the reference to us under the heading "Experts" in such Prospectus.

Deloitte & Touche LLP

Parsippany, New Jersey
October 5, 2001
UNITED STATES ENVIRONMENTAL PROTECTION AGENCY 

REGION 2 

290 BROADWAY 

NEWYORK, NY 10007-1866 

Miles M. Croom 

Assistant Regional Administrator 

NOAA Fisheries, Southeast Regional Office 

Habitat Conservation Division 

263 13th Avenue South 

St. Petersburg, FL 33701 

Dear Mr. Croom: 

AUG 2 3 2005 

Thank you for your letter of May 13,2005 providing NOAA National Marine Fisheries 

Service's fmmal Essential Fish Habitat (EFH) recommendations on the modifications to 

the designations of the ocean dredged material disposal sites around Puerto Rico (at 40 

CFR 228.16) that are being contemplated by the U.S. Environmental Protection Agency. 

In your letter you recommend that EFH be mapped in areas where dredging is anticipated 

to facilitate future EFH consultations for individual projects. 

On July 11, 2005 our staff met at your offices in Cabo Rojo to further discuss this 

recmmnendation. We agreed at that meeting that large scale mapping ofEFH at this time 

is impractical but that EPA should continue to compile information on benthic habitat 

that has become available through benthic surveys and other EFH mapping studies to 

identify potential routes for transport of sediment laden barges. Critical or potential 

areas ofEFH identified along those routes would then be evaluated as part ofEFH 

consultations for individual projects before a permit will be issued. 

If you have any further questions about the proposed action, please do not hesitate to 

contact Mark Reiss at (212) 637-3799. 

_,/·-?' 

Thank you· ~~~----~--;' _ .... ---- _;_~~-;"""' .· --c( __ .. _______________ _ c ___ .... -- / __ 1 .... .--- ... --·- . / '"'-(_'"""'· c r-;;- -::...~ .. ·· £ ' // L 

Douglas!Pjlbst 

Teamieider 

Dreefged Material Management Team 

Drvision of Environmental Planning and Protection 

Cc: Lisamarie Carrubba, PhD 

Internet Address (URL) • http://www.epa.gov 

Recycled/Recyclable •Printed with Vegetable Oil Based Inks on 100% Postconsumer, Process Chlorine Free Recycled Paper
#### Nelson Logan *v.*Edison Lenhart et al.

*Timothy C. Moynahan,*on the motion for the plaintiff.

*Irving W. Pasternak, on*the motion for the defendants.

Submitted March *24*

decided March 25, 1969

The motion by the parties for approval and acceptance of their stipulation to have the appeal from the Court of Common Pleas for the judicial district of Waterbury decided on the briefs and record without oral argument is granted.
<PAGE>   1

                                                                    EXHIBIT 23.1

               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS


     We consent to the reference to our firm under the captions "Summary
Consolidated Financial and Other Data," "Selected Consolidated Financial and
Other Data" and "Experts" and to the use of our reports dated February 12, 1999,
except note 12, as to which the date is October 7, 1999 in the Registration
Statement (Form S-1 No. 333-85779) and the related Prospectus of Illuminet
Holdings, Inc. for the registration of shares of its common stock.



                                                          ERNST & YOUNG LLP


Seattle, Washington

October 7, 1999
##### 



Exhibit 99.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Ambassadors International, Inc. (the
Company) on Form 10-K for the year ended December 31, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the Report), the
undersigned, John Ueberroth, Chief Executive Officer of the Company, and
Timothy Fogarty, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:



| | (1) |  | The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and                               
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------
|
| | (2) |  | The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of
the Company.

/s/ John A. Ueberroth
John A. Ueberroth
Chief Executive Officer
March 28, 2003

/s/ Timothy T. Fogarty
Timothy T. Fogarty
Chief Financial Officer
March 28, 2003
§ 814.124 Institutional Review Board requirements. ( a ) *IRB approval.* The HDE holder is responsible for ensuring that a HUD approved under this subpart is administered only in facilities having oversight by an Institutional Review Board (IRB) constituted and acting pursuant to part 56 of this chapter, including continuing review of use of the device. In addition, a HUD may be administered only if such use has been approved by an IRB. If, however, a physician in an emergency situation determines that approval from an IRB cannot be obtained in time to prevent serious harm or death to a patient, a HUD may be administered without prior approval by an IRB. In such an emergency situation, the physician shall, within 5 days after the use of the device, provide written notification to the chairman of the IRB of such use. Such written notification shall include the identification of the patient involved, the date on which the device was used, and the reason for the use.
( b ) *Withdrawal of IRB approval.* A holder of an approved HDE shall notify FDA of any withdrawal of approval for the use of a HUD by a reviewing IRB within 5 working days after being notified of the withdrawal of approval.
[61 FR 33244, June 26, 1996, as amended at 63 FR 59221, Nov. 3, 1998; 82 FR 26349, June 7, 2017]
118TH CONGRESS 

2D SESSION H. R. 7686 

AN ACT 

To amend the Research and Development, Competition, and 

Innovation Act to clarify the definition of foreign country 

for purposes of malign foreign talent recruitment restriction, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 7686 EH

1 SECTION 1. CLARIFICATION OF DEFINITION OF FOREIGN 

2 COUNTRY FOR PURPOSES OF MALIGN FOR3 EIGN TALENT RECRUITMENT RESTRICTION. 

4 Paragraph (4) of section 10638 of title VI of division 

5 B of the Research and Development, Competition, and In6 novation Act is amended— 

7 (1) by inserting ‘‘of concern’’ after ‘‘foreign 

8 country’’ each place such term appears; 

9 (2) by striking ‘‘means—’’ and all that follows 

10 through ‘‘any program, position, or activity’’ and in11 serting ‘‘means any program, position, or activity’’; 

12 (3) by striking subparagraph (B); 

13 (4) by redesignating clauses (i) through (ix) as 

14 subparagraphs (A) through (I), respectively, and 

15 moving such subparagraphs, as so redesignated, two 

16 ems to the left; 

17 (5) in the matter preceding subparagraph (A), 

18 as so redesignated, by striking ‘‘directly provided’’ 

19 and inserting ‘‘whether directly or indirectly pro20 vided’’; and 
3 

•HR 7686 EH

1 (6) in subparagraph (I), as so redesignated, by 

2 striking ‘‘; and’’ and inserting a period. 

Passed the House of Representatives September 9, 

2024. 

Attest: 

Clerk. 
118TH CONGRESS 

2D SESSION H. R. 7686 

AN ACT 

To amend the Research and Development, Competiposes. talent recruitment restriction, and for other pur- of foreign country for purposes of malign foreign tion, and Innovation Act to clarify the definition
Exhibit 23.1





Consent of Independent Registered Public Accounting Firm














Hemispherx Biopharma, Inc.


Philadelphia, Pennsylvania








We consent to the incorporation by reference in Registration Statements (No.s 333-160499, 333-57134, 118903 and 333-155528) on Form S-8 and Registration Statements (No.s 333-136187, 333-117178,  333-119017, 333-108645, 333-111135, 333-113796, 333-130008, 333-159856 and 333-151696) on Form S-3 of Hemispherx Biopharma, Inc. and Subsidiaries of our report dated March 19, 2015 relating to our audit of the consolidated financial statements which appears in this Annual Report on Form 10-K of Hemispherx Biopharma, Inc. for the year ended December 31, 2014.








/s/ McGladrey LLP


McGladrey LLP





Blue Bell, Pennsylvania


March 19, 2015
Final Listing of Questionnaire Files for Steam Electric Rulemaking Record

Plant ID 06453

Removed 

from Public 

(Non-CBI) 

Docket1

Copyright 

Flag2

File Name Description

x 06453\06453_Checklist_110410_version34.xls EPA Technical Review Checklist Workbook

06453\06453_Completeness_Checklist.xls EPA Completeness Review Checklist

06453\06453_HardcopyLog.doc EPA log of hardcopy documents submitted

x 06453\06453_PartA.xls Plant submitted survey file

x 06453\06453_PartE.xls Plant submitted survey file

x 06453\06453_PartH.xls Plant submitted survey file

06453\Certification Statement_06543.pdf Plant certification statement

06453\Supporting Documentation\06453_Stanton MAP-1.pdf Plant submitted supplemental files to the survey

x 06453\Supporting Documentation\06453_Stanton Water Balance.pdf Plant submitted supplemental files to the survey

1

 Final reviewed survey responses are located in the Steam Electric Technical Questionnaire Database . 

2

 Copyright documents are available from the docket.
Editorial Note on Part 316
Editorial Note: Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

§ 316.23 Timing of requests for orphan-drug designation; designation of already approved drugs. ( a ) A sponsor may request orphan-drug designation at any time in its drug development process prior to the time that sponsor submits a marketing application for the drug for the same rare disease or condition.
( b ) A sponsor may request orphan-drug designation of an already approved drug for an unapproved use without regard to whether the prior marketing approval was for a rare disease or condition.
[78 FR 35133, June 12, 2013]
# C_2016048EN.01009101.xml

| 8.2.2016 | EN | Official Journal of the European Union | C 48/91 |
| --- | --- | --- | --- |

8.2.2016

EN

Official Journal of the European Union

C 48/91

---

Judgment of the Civil Service Tribunal (Single Judge) of 18 December 2015 — De Nicola v EIB

(Case F-9/14) (1)

1

((Civil Service - EIB staff - Appraisal - 2012 staff report - Unlawfulness of the decision of the Adjudication Panel - Refusal of promotion - No need to adjudicate))

(2016/C 048/102)

Language of the case: Italian

Parties

Parties

Applicant: Carlo De Nicola (Strassen, Luxembourg) (represented by: L. Isola, lawyer)

Applicant:

Defendant: European Investment Bank (represented by: G. Nuvoli and F. Martin, acting as Agents)

Defendant:

Re:

Re:

Application, firstly, for annulment of the applicant’s staff report for 2012 as regards the sections concerning ‘appraisal’, ‘assessment’ and ‘setting of objectives for 2013’ and in so far as it does not propose that he be promoted to Function D and, next, annulment of the note to staff No 722 of 5 December 2012 and the 2012 Guide to Staff Appraisal Procedure or a declaration that they are inapplicable and, secondly, a finding of psychological harassment of the applicant. Finally, application for an order that the EIB pay compensation for the material and non-material damage suffered.

Operative part of the judgment

Operative part of the judgment

The Tribunal:

| 1. | Annuls the decision of the Adjudication Panel of the European Investment Bank of 23 October 2013; |
| --- | --- |

1.

Annuls the decision of the Adjudication Panel of the European Investment Bank of 23 October 2013;

| 2. | Holds that there is no need to adjudicate on the pleas seeking annulment of the staff report relating to 2012 and all connected, consequent and prior acts; |
| --- | --- |

2.

Holds that there is no need to adjudicate on the pleas seeking annulment of the staff report relating to 2012 and all connected, consequent and prior acts;

| 3. | Dismisses the remainder of the action; |
| --- | --- |

3.

Dismisses the remainder of the action;

| 4. | Orders the European Investment Bank to bear its own costs and to pay the costs incurred by Mr D Nicola. |
| --- | --- |

4.

Orders the European Investment Bank to bear its own costs and to pay the costs incurred by Mr D Nicola.

---

(1)  OJ C 212, 7.7.2014, p. 44.

1

---
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1145 Calcium test system. ( a ) *Identification.* A calcium test system is a device intended to measure the total calcium level in serum. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany (intermittent muscular contractions or spasms).
( b ) *Classification.* Class II.